Eli Lilly Raises 2025 Outlook After Mounjaro, Zepbound Sales Surge
We see Eli Lilly making waves with its bold decision to raise its 2025 sales guidance to $60 billion to $62 billion. This comes after a stellar second quarter, where revenue hit $15.56 billion, thanks to soaring sales of Mounjaro and Zepbound. For the stock market, this signals a bright future, though not without some hurdles like government pressure on drug prices.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
